Strategic Intelligence Report
Generated July 29, 2026
Neurotechnology
Neuralink
Strategic importance is our editorial rating of how central this entity is to the technology landscape we track; confidence reflects how well-sourced and current the underlying evidence is.
1
Chokepoint Score
1 other entity structurally depend on this one
Cooling
Activity
0 recorded changes in the last 90 days
Headquarters
Fremont, California, USA
Website
Employees
600 (2026, approximate)
Founded
2016
Listing
private
Overview
Elon Musk's brain-computer interface company implanting its N1 device via the R1 surgical robot, running the PRIME trial (quadriplegia/ALS patients controlling computers and robotic arms via thought) and the VOICE trial (decoding speech from thought). Neuralink reached its 26th human trial participant in 2026, up from 21 in January, after expanding trials to the UAE, UK and Canada, and raised a $650 million Series E in April 2026 at a roughly $9 billion valuation, bringing total funding to about $1.85 billion since founding.
Dependency Map
One hop in each direction — see Strategic Connections below for the full, sourced breakdown of every relationship.
Strategic Connections
Development
- Brain-Computer Interfaces: Neuralink develops the N1 implantable brain-computer interface and R1 surgical robot.
Competition / Other
- Synchron: Neuralink competes with Synchron and Precision Neuroscience in the race toward the first FDA-approved implantable brain-computer interface.
- Precision Neuroscience: Neuralink competes with Precision Neuroscience, which has taken a less invasive cortical-surface-electrode approach to reach clinical milestones faster.
- Paradromics: Neuralink competes with Paradromics, which completed the first-in-human implant of its wireless Connexus BCI at the University of Michigan in 2026 targeting speech restoration.
Strategic Risks
- Surgical brain implant procedures carry inherent safety and regulatory risk
- Small trial populations and long FDA approval timelines
- Public scrutiny over Elon Musk-affiliated ventures
Future Outlook
- Pursuing high-volume production and a more automated surgical procedure starting 2026
- Expanding international trial footprint (UAE, UK, Canada) ahead of a first commercial approval
- Blindsight vision-restoration trial and new FDA-experienced medical affairs leadership signal a broadening clinical platform strategy
Sources
- Basenor / MobiHealthNews (Jun 2026) — Neuralink reaches 26th patient in ongoing brain-computer interface trials
- Sacra / Tracxn (May 2026) — Neuralink raises $650M Series E at ~$9B valuation
- Interesting Engineering / Fierce Biotech (Jan 2026) — Neuralink advances Blindsight vision implant, hires former FDA executive
Generated by InsightNodes — Technology Intelligence Platform. This report reflects sourced, evidence-backed information as of the dates cited above and is not investment advice.
Viewing the Full Analyst Report — switch to the Executive Summary.